- Biofrontera AG (BFRA +1.6%) has reported preliminary revenue of €2.63M (+50% Y/Y) for the month of June.
- Further to factor out the pandemic impact, product sales was up 19% for the month, and was €7.59M for Q2 2021 up 10% compared to Q2 2019.
- Region-wise monthly sales vs. 2019: U.S. €1.37M (-10%); Germany, €0.42M (+35%); Rest of Europe, €0.83M (+131% Y/Y).
- The company noted that sales in June this year include the first batch of Ameluz for reintroduction in the Scandinavian market by Galenica AB.
- Previously (June 7): Biofrontera reports prelim product sales revenue growth of 108% in May